ES2140463T3 - Prevencion y tratamiento de la neuropatia periferica. - Google Patents

Prevencion y tratamiento de la neuropatia periferica.

Info

Publication number
ES2140463T3
ES2140463T3 ES93915178T ES93915178T ES2140463T3 ES 2140463 T3 ES2140463 T3 ES 2140463T3 ES 93915178 T ES93915178 T ES 93915178T ES 93915178 T ES93915178 T ES 93915178T ES 2140463 T3 ES2140463 T3 ES 2140463T3
Authority
ES
Spain
Prior art keywords
peripheral neuropathy
prevention
treatment
igf
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93915178T
Other languages
English (en)
Inventor
Michael E Lewis
Stuart C Apfel
John A Kessler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albert Einstein College of Medicine
Cephalon LLC
Original Assignee
Albert Einstein College of Medicine
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/051,191 external-priority patent/US5420112A/en
Application filed by Albert Einstein College of Medicine, Cephalon LLC filed Critical Albert Einstein College of Medicine
Application granted granted Critical
Publication of ES2140463T3 publication Critical patent/ES2140463T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Surgical Instruments (AREA)
  • External Artificial Organs (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA INVENCION DESCRIBE UN METODO PARA USAR EL FACTOR DE CRECIMIENTO SIMILAR A LA INSULINA I (IGF-I) O EL FACTOR DE CRECIMIENTO SIMILAR A LA INSULINA III (IGF-III) PARA PREVENIR O TRATAR LA NEUROPATIA PERIFERICA EN UN MAMIFERO.
ES93915178T 1992-06-12 1993-06-01 Prevencion y tratamiento de la neuropatia periferica. Expired - Lifetime ES2140463T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89907092A 1992-06-12 1992-06-12
US08/051,191 US5420112A (en) 1992-06-12 1993-04-16 Prevention and treatment of peripheral neuropathy

Publications (1)

Publication Number Publication Date
ES2140463T3 true ES2140463T3 (es) 2000-03-01

Family

ID=26729153

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93915178T Expired - Lifetime ES2140463T3 (es) 1992-06-12 1993-06-01 Prevencion y tratamiento de la neuropatia periferica.

Country Status (16)

Country Link
US (3) US5569648A (es)
EP (1) EP0659083B1 (es)
JP (1) JP3623502B2 (es)
AT (1) ATE187889T1 (es)
AU (1) AU683215B2 (es)
CA (1) CA2136969C (es)
DE (1) DE69327402T2 (es)
DK (1) DK0659083T3 (es)
ES (1) ES2140463T3 (es)
FI (1) FI945840A0 (es)
GR (1) GR3032844T3 (es)
HU (1) HU217543B (es)
NO (1) NO309705B1 (es)
NZ (2) NZ253867A (es)
PT (1) PT659083E (es)
WO (1) WO1993025219A1 (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2176708A1 (en) * 1993-11-15 1995-05-26 Christopher A. Maack Method of treating neurological disorders
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
DE69835878T2 (de) * 1997-05-05 2007-04-26 Mayo Foundation For Medical Education And Research, Rochester IGFIIE/ IGFBP2 Komplex
US6548482B1 (en) 1997-05-05 2003-04-15 Mayo Foundation For Medical Education And Research Treatment of osteoporosis
US6916790B2 (en) 1997-05-05 2005-07-12 Mayo Foundation For Medical Education And Research Treatment of osteoporosis
US6417160B1 (en) 1997-10-14 2002-07-09 Nadine A. Tatton Methods for increasing schwann cell survival
PT1047449E (pt) * 1997-10-28 2004-04-30 Univ British Columbia Composicoes imunologicas e metodos de utilizacao para alterar transitoriamente a mielina do sistema nervoso central mamifero para promover a regeneracao neuronal
ES2146530B1 (es) * 1997-12-26 2001-04-16 Consejo Superior Investigacion Utilizacion del factor de crecimiento igf-i en la fabricacion de composiciones utiles en el tratamiento de la ataxia cerebelar.
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
PT1141014E (pt) 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
US6339085B1 (en) 1999-03-08 2002-01-15 The University Of Manitoba Therapeutics for cardiovascular and related diseases
US20050008641A1 (en) * 1999-04-28 2005-01-13 University Of British Columbia Composition for neuronal regeneration comprising myelin-specific antibodies and complement proteins
US6489345B1 (en) 1999-07-13 2002-12-03 Medicure, Inc. Treatment of diabetes and related pathologies
EP1872797A3 (en) * 1999-08-24 2008-04-02 Medicure International Inc. Treatment of cardiovascular and related pathologies
US6770468B1 (en) 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
US6534300B1 (en) * 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US7442689B2 (en) * 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
JP2003525303A (ja) 2000-02-29 2003-08-26 メディキュア インターナショナル インコーポレイテッド 心臓保護ホスホン酸塩およびマロン酸塩
EP1278526A2 (en) 2000-03-28 2003-01-29 Medicure International Inc. Treatment of cerebrovascular disease
EP1282437B1 (en) 2000-05-16 2008-03-19 Genentech, Inc. Treatment of cartilage disorders
US6897228B2 (en) * 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
ATE364595T1 (de) 2000-07-07 2007-07-15 Medicure Int Inc Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
US6548519B1 (en) 2001-07-06 2003-04-15 Medicure International Inc. Pyridoxine and pyridoxal analogues: novel uses
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
WO2002014537A2 (en) * 2000-08-14 2002-02-21 Fallon Joan M Methods for diagnosing and treating dysautonomia and other dysautonomic conditions
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
WO2002051981A2 (en) 2000-12-13 2002-07-04 Baylor College Of Medecine Defects in periaxin associated with myelinopathies
HUP0500733A3 (en) 2001-02-09 2010-01-28 Genentech Inc Crystallization of igf-1
US20040121988A1 (en) * 2001-03-28 2004-06-24 Medicure International Inc. Treatment of cerebrovascular disease
DE60232880D1 (de) 2001-05-24 2009-08-20 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
US7605177B2 (en) * 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7714020B2 (en) * 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US20070004641A1 (en) * 2001-05-24 2007-01-04 Neuren Pharmaceuticals Limited Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
US20030124652A1 (en) * 2001-12-21 2003-07-03 Novazyme Pharmaceuticals, Inc. Methods of producing high mannose glycoproteins in complex carbohydrate deficient cells
US6800472B2 (en) * 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
US6905856B2 (en) 2001-12-21 2005-06-14 Genzyme Glycobiology Research Institute, Inc. Soluble GlcNAc phosphotransferase
ES2207387B1 (es) * 2002-02-28 2005-07-16 Consejo Sup. Investig. Cientificas Composicion quimica de igf-i para el tratamiento y prevencion de enfermedades neurodegenerativas.
US20040186077A1 (en) * 2003-03-17 2004-09-23 Medicure International Inc. Novel heteroaryl phosphonates as cardioprotective agents
EP1773370A1 (en) * 2004-07-07 2007-04-18 Medicure International Inc. Combination therapies employing platelet aggregation drugs
US20070060549A1 (en) * 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
AU2005279758A1 (en) * 2004-08-30 2006-03-09 Tercica, Inc. Method and device for diagnosing and treating insulin-like growth factor deficiency disorders
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
US20060094749A1 (en) * 2004-10-28 2006-05-04 Medicure International Inc. Substituted pyridoxines as anti-platelet agents
US7459468B2 (en) * 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
WO2006050598A1 (en) * 2004-10-28 2006-05-18 Medicure International Inc. Dual antiplatelet/anticoagulant pyridoxine analogs
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
WO2007059631A1 (en) * 2005-11-28 2007-05-31 Medicure International Inc. Selected dosage for the treatment of cardiovascular and related pathologies
US8658163B2 (en) * 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) * 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) * 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
PL2318035T3 (pl) * 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
CN105031628B (zh) 2009-01-06 2020-10-02 加尔纳根有限责任公司 治疗或预防大肠杆菌导致的经口感染的组合物和方法
KR20170005192A (ko) 2009-01-06 2017-01-11 큐어론 엘엘씨 스타필로코쿠스 아우레우스 감염의 치료 또는 예방 및 표면 상의 스타필로코쿠스 아우레우스의 박멸 또는 감소를 위한 조성물 및 방법
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
WO2011109448A1 (en) * 2010-03-05 2011-09-09 Baylor Research Institute Involvement of androgen/androgen receptor pathway in fabry disease
CN103370074B (zh) * 2011-01-26 2015-09-02 雪印惠乳业株式会社 感觉改善剂
AU2012245287B2 (en) 2011-04-21 2017-04-13 Curemark, Llc Compounds for the treatment of neuropsychiatric disorders
EP2771367B1 (en) 2011-10-25 2017-12-06 Indiana University Research and Technology Corporation Gigaxonin fusion protein and methods for treating giant axonal neuropathy
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1275922C (en) * 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
ATE116335T1 (de) * 1987-12-24 1995-01-15 Gropep Pty Ltd Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2).
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
EP0597033B1 (en) * 1991-08-01 1997-04-09 Genentech, Inc. Igf-1 to improve the neural condition
US5420112A (en) * 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy

Also Published As

Publication number Publication date
AU683215B2 (en) 1997-11-06
US5648335A (en) 1997-07-15
PT659083E (pt) 2000-05-31
JPH07507799A (ja) 1995-08-31
NZ280523A (en) 1997-07-27
CA2136969C (en) 2009-03-24
NO944780D0 (no) 1994-12-09
GR3032844T3 (en) 2000-07-31
EP0659083B1 (en) 1999-12-22
US5569648A (en) 1996-10-29
HU217543B (hu) 2000-02-28
WO1993025219A1 (en) 1993-12-23
DE69327402D1 (de) 2000-01-27
CA2136969A1 (en) 1993-12-23
NO309705B1 (no) 2001-03-19
HU9403544D0 (en) 1995-02-28
ATE187889T1 (de) 2000-01-15
NO944780L (no) 1994-12-09
US5633228A (en) 1997-05-27
JP3623502B2 (ja) 2005-02-23
DK0659083T3 (da) 2000-06-13
FI945840A0 (fi) 1994-12-12
EP0659083A1 (en) 1995-06-28
AU4526293A (en) 1994-01-04
EP0659083A4 (en) 1996-03-20
NZ253867A (en) 1996-08-27
DE69327402T2 (de) 2000-05-04
HUT70450A (en) 1995-10-30

Similar Documents

Publication Publication Date Title
ES2140463T3 (es) Prevencion y tratamiento de la neuropatia periferica.
DE69427869T2 (de) Botulinumtoxine zur behandlung von hyperhydrosis
EP0783378A4 (en) TREATMENT OF NYLON AND OTHER TEXTILES
DE69010893T2 (de) Verfahren zur behandlung von koks sowie löschen desselben.
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
HU9301272D0 (en) Method for treating inflammations and wounds using plasminogene activator inhibitors
GR3015490T3 (en) Composition and method for the treatment of osteoporosis in mammals.
DE69220051D1 (de) Vorrichtung zur Behandlung von Getreide
DE69404785D1 (de) Vorrichtung zur Behandlung von Oberflächen
DE69304233D1 (de) Vorrichtung zur Behandlung von Wasser
DE69421196T2 (de) Vorrichtung zur behandlung von überbiss
NZ247406A (en) Treatment of osteoporosis with 1 alpha, 24(r)-dihydroxy-22(e)-dehydro-vitamin d3
DE69403871D1 (de) Vorrichtung zur Behandlung von Oberflächen
GB2271509B (en) Antivenom immunesera
EP0622487A3 (en) Enzymatic composition for the treatment of sticky cotton fibers and method for the treatment of sticky cotton fibers with this enzymatic composition.
ZA965346B (en) Methods of treating neuropeptide Y-associated conditions.
DE68907569D1 (de) Mittel zur behandlung oder vorbeugung von aids.
FR2690330B1 (fr) Dispositif destine a traiter certaines fractures siegeant entre massif trochanterien et 1/3 moyen de la diaphyse femorale.
DE9320159U1 (de) Vorrichtung zur magnetischen Behandlung von Wasser
GR3020172T3 (en) Sterilant mixture and sterilization method.
GB2269523B (en) Treating hides
DE9218403U1 (de) Vorrichtung zur magnetischen Behandlung von Wasser
EP0614364A4 (en) METHODS AND COMPOSITIONS FOR TREATING INFECTIONS USING OPTICALLY PURE (S) -LOMEFLOXACIN.
MX9407703A (es) METODO PARA EL TRATAMIENTO DEL CHOQUE PUTREFACTIVO UTILIZANDO TIMOSINAa1.
ZA965345B (en) Methods of treating neuropeptide Y-associated conditions.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 659083

Country of ref document: ES